RBC Capital initiated coverage with an Outperform rating and a $340 price target, citing the company's market position and potential growth in Type 2 diabetes. Bernstein raised its price target to $335, noting Insulet's strong performance and growth prospects. Stifel increased its target to $293, maintaining a Hold rating, while Canaccord Genuity raised its target to $324, emphasizing Insulet's strategic market position. BTIG set its price target at $310, highlighting the company's strong revenue performance and optimistic outlook for margin expansion. Insulet's recent developments include a focus on expanding its presence in the Type 2 diabetes market, with over 30% of new U.S. patients in the fourth quarter starting on Insulet's products being Type 2 diabetes patients. The company is also expanding its U.S. sales force and increasing prescribers for Type 2 diabetes.